Waterproof, sweat-resistant and mosquito-repellent set and its application

Abstract

The present invention provides a long-lasting mosquito repellent suit, which comprises: (i) formulation A, the formulation A comprising: 10-20 weight% of grease, 0.01-30 weight% of mosquito repellent, 3-25 weight% of hydrogenated polydimethylsiloxane, 5-35 weight% of vinyl polydimethylsiloxane, 1-10 weight% of emulsifier, optionally 1-10 weight% of silica, and an acceptable carrier in the field of personal care; and (ii) formulation B, the formulation B comprising: 1-10 weight% of colloidal platinum composition, 1-10 weight% of light scattering particles, and an acceptable carrier in the field of personal care; wherein the colloidal platinum composition comprises: 0.1-10 weight% of a metal platinum salt, 1-20 weight% of a fatty acid having 8-30 carbon atoms, 0.01-5 weight% of an organosilane having 10-60 carbon atoms, and an acceptable solvent in the field of personal care, wherein the solvent is propylene glycol. The present invention also relates to the application of the suit in the field of personal care.

Description

Technical Field

[0001] The present invention relates to a mosquito and insect repellent product in the field of daily chemicals, and in particular to a waterproof, sweat-resistant, long-lasting mosquito and insect repellent suit and application thereof. Background Art

[0002] Mosquito bites are a key means of transmitting some diseases. For example, over 40 mosquito-borne diseases have been reported, including yellow fever, Western equine encephalitis, West Nile virus disease, malaria, Japanese encephalitis, and dengue fever. Furthermore, the incidence of insect-borne diseases has shown a significant upward trend worldwide in recent years. New mosquito-borne diseases, such as Rift Valley fever and West Nile fever, have also been discovered. Furthermore, the prevalence of existing mosquito-borne diseases continues to expand, and their frequency continues to increase.

[0003] Preventing mosquito bites isn't just a daily problem for people; it's also a long-standing issue for military, police, and other field workers. The spread of these diseases poses a serious threat to health and life. Consequently, humans have developed various methods to repel mosquitoes. One of the most effective and popular methods is the use of mosquito repellent. For home use, mosquito repellents are available in the form of electric mosquito coils and combustible mosquito coils. For outdoor use, the most popular options are mosquito repellent stickers, sprays, wristbands, and portable heated devices. However, in hot, humid, and sweaty outdoor environments, the use of mosquito repellent stickers and portable heated devices is severely limited: stickers easily fall off, compromising their effectiveness. Portable heated devices are susceptible to moisture, causing short circuits and power outages. Furthermore, being strapped to the body makes them inconvenient and cumbersome to use. Mosquito repellent bracelets, which are made by mixing mosquito repellent into a polymer material and molding them through injection molding, have a weak sustained-release rate and a small repellent coverage area, making them unsuitable for large-scale use. Although mosquito repellent spray can be used on a large area, some products claim to repel mosquitoes for 4-8 hours by adding encapsulated dicedin or mixing water-soluble polymer film-forming agents into the spray. However, with sweating or the influence of external objects on the skin, these mosquito repellent encapsulations or water-soluble polymer film-forming agents will be destroyed and lost, thereby greatly reducing the mosquito repellent effect.

[0004] Therefore, this field needs to develop a new technology that meets the requirements of long-lasting mosquito repellent, easy use, large-area use on the skin, and applicability to all-weather field environments (waterproof and sweat-resistant), so as to better solve the pain points of consumers, including field workers, soldiers, police, etc., help improve the quality of life and work efficiency, and even contribute to national defense construction. Summary of the Invention

[0005] In one aspect, the present invention provides a long-lasting mosquito and insect repellent kit comprising:

[0006] (i) Dosage form A, comprising:

[0007] 10-20% by weight of fat,

[0008] 0.01-30% by weight of mosquito repellent,

[0009] 3-25 wt% of hydrogenated polydimethylsiloxane having a viscosity of 10 to 130 cSt at 25°C,

[0010] 5-35% by weight of vinyl polydimethylsiloxane having a viscosity of 55,000 to 95,000 cSt at 25°C,

[0011] 1-10% by weight of an emulsifier,

[0012] Optionally, 1-10 wt% silica, and

[0013] A personal care acceptable carrier; and

[0014] (ii) Dosage Form B, comprising:

[0015] 1-10% by weight of a colloidal platinum composition,

[0016] 1-10% by weight of light scattering particles,

[0017] An acceptable carrier in the field of personal care;

[0018] Wherein, the colloidal platinum composition comprises:

[0019] 0.1-10% by weight of a metal platinum salt,

[0020] 1-20% by weight of fatty acids having 8-30 carbon atoms,

[0021] 0.01-5% by weight of an organosilane having 10-60 carbon atoms,

[0022] A personal care acceptable solvent, the solvent is propylene glycol.

[0023] In a preferred embodiment, the emulsifier in the formulation A is dimethicone PEG-10 / 15 crosspolymer.

[0024] In a preferred embodiment, the silica in the dosage form A is selected from the group consisting of silica, silica silylate, silica dimethyl silylate, polydimethylsiloxane silica silylate, hydrated silica, or a combination thereof.

[0025] In a preferred embodiment, the colloidal platinum composition in the dosage form B further comprises polyvinyl pyrrolidone having a K value of 28-34.

[0026] In a preferred embodiment, the metal platinum salt in the colloidal platinum composition in the dosage form B is selected from: chloroplatinic acid, potassium hexachloroplatinate, sodium chloroplatinate, platinum acetylacetonate, or a combination thereof.

[0027] In a preferred embodiment, the fatty acid in the colloidal platinum composition in the dosage form B is selected from palmitic acid, oleic acid, stearic acid, lauric acid, behenic acid, or a combination thereof.

[0028] In a preferred embodiment, the organosilane in the colloidal platinum composition in Formulation B is selected from: trimethoxyoctylsilane, triethoxyoctylsilane, or a combination thereof.

[0029] In a preferred embodiment, the light scattering particles in the dosage form B are nylon-12 and isopropyl titanium triisostearate.

[0030] In a preferred embodiment, the formulation B further comprises the following ingredients: silicone oil, silicone elastomer, emulsifier, polyol or a combination thereof.

[0031] In a preferred embodiment, the kit of the present invention is in the form of a dual-dose package or two separate packages.

[0032] In another aspect, the present invention provides a use of the kit in the field of personal care, for achieving a long-lasting mosquito and insect repellent effect.

[0033] In another aspect, the present invention also relates to a method for using the kit, comprising applying formulation A evenly to the skin surface until absorbed, and then applying formulation B to the skin surface. In a preferred embodiment, the skin surface refers to an area that is easily exposed and susceptible to mosquito bites. DETAILED DESCRIPTION

[0034] The present invention provides a waterproof, sweat-resistant, long-lasting mosquito and insect repellent kit comprising formulations A and B. Formulation A, applied in the first step, comprises a mosquito repellent, film-forming monomers vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, and silica. Formulation B, applied in the second step, comprises colloidal platinum and light-scattering particles. After using the waterproof, sweat-resistant, long-lasting mosquito and insect repellent kit prepared according to the present invention, test subjects developed a uniform, light, and evenly applied mosquito and insect repellent coating on their skin. Surprisingly, the test results demonstrated a long-lasting mosquito and insect repellent effect of 15 hours or more.

[0035] In order to provide a more concise description, some quantitative expressions given herein are not modified by the term "about". It should be understood that, regardless of whether the term "about" is explicitly used, each quantity given herein is intended to refer to the actual given value and also to refer to the approximate value of these given values that can be reasonably estimated by a person of ordinary skill in the art, including the approximate value of these given values caused by experimental and / or measurement conditions.

[0036] To provide a more concise description, some quantitative expressions herein are described as a range of about X amount to about Y amount. It should be understood that when a range is described, the range is not limited to the upper and lower limits described, but should include the entire range of about X amount to about Y amount or any amount therebetween.

[0037] I.Dosage Form A

[0038] Formulation A in the long-lasting mosquito and insect repellent kit described in the present application is a product applied in the first step, and the product comprises a mosquito repellent, vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, an emulsifier and optionally silica.

[0039] Insect repellent

[0040] The mosquito repellents contained in the formulation A of the set of the present invention are collectively referred to as immonim (3-(N-n-butylacetamido)-ethyl propionate), DEET (N,N-diethyl-3-methylbenzamide), PMD (p-menthyl-3,8-diol), DEPA (N,N-diethylphenylacetamide), hydroxypiperidin (isobutyl hydroxyethylpiperidinecarboxylate), oil of lemon eucalyptus (OLE), etc.

[0041] In some embodiments of the present invention, the insect repellent content of Formulation A of the kit described herein is 0.01-30% by weight. In some embodiments of the present invention, Formulation A of the kit comprises 0.1%-20% by weight of the insect repellent. In some embodiments of the present invention, Formulation A of the kit comprises 0.5%-10% by weight of the insect repellent. In some embodiments of the present invention, Formulation A of the kit comprises 1%-10% by weight of the insect repellent.

[0042] Siloxane

[0043] Formulation A of the set of the present invention contains vinyl dimethicone, whose INCI name is VINYLDIMETHICONE. The viscosity specification of the vinyl dimethicone used in the present invention is required to be 55,000 to 95,000 cSt at 25°C. In a preferred embodiment, the viscosity of the vinyl dimethicone used in the present invention is 55,000 to 80,000 cSt. In a preferred embodiment, the viscosity of the vinyl dimethicone used in the present invention is 60,000 to 80,000 cSt.

[0044] In some embodiments of the present invention, the content of vinyl dimethicone in the dosage form A of the kit described herein is 5-50% by weight. In some embodiments of the present invention, the dosage form A of the kit comprises 5-35% by weight of vinyl dimethicone. In some embodiments of the present invention, the dosage form A of the kit comprises 5-20% by weight of vinyl dimethicone.

[0045] Formulation A of the kit of the present invention contains hydrogenated dimethicone, whose INCI name is HYDROGENDIMETHICONE. The viscosity of the hydrogenated dimethicone used in the present invention is required to be 10 to 130 cSt at 25°C. In a preferred embodiment, the viscosity of the hydrogenated dimethicone used in the present invention is 15 to 100 cSt.

[0046] In some embodiments of the present invention, the content of hydrogenated polydimethylsiloxane in the formulation A of the kit described herein is 1-35% by weight. In some embodiments of the present invention, the formulation A of the kit comprises 3-25% by weight of hydrogenated polydimethylsiloxane. In some embodiments of the present invention, the formulation A of the kit comprises 5-20% by weight of hydrogenated polydimethylsiloxane.

[0047] Silicones (e.g., hydrogenated polydimethylsiloxane and / or vinyl polydimethylsiloxane in Formulation A) crosslink on-site on the skin (e.g., by the action of colloidal platinum in Formulation B) to form a transparent invisible film with properties such as water resistance and sweat resistance.

[0048] emulsifiers

[0049] The dosage form A of the kit of the present invention comprises an emulsifier. In a specific embodiment, the emulsifier used in dosage form A is polydimethylsiloxane PEG-10 / 15 crosspolymer.

[0050] In some embodiments of the present invention, the content of dimethicone PEG-10 / 15 crosspolymer in the dosage form A of the kit described herein is 1-10% by weight. In some embodiments of the present invention, the dosage form A of the kit comprises 1-5% by weight of dimethicone PEG-10 / 15 crosspolymer. In some embodiments of the present invention, the dosage form A of the kit comprises 2-5% by weight of dimethicone PEG-10 / 15 crosspolymer.

[0051] silica

[0052] The dosage form A of the kit of the present invention optionally contains silica. The silica used in the dosage form A is a general term including silica, silica silylate, silica dimethyl silylate, silica polydimethylsiloxane silylate, hydrated silica and other combinations.

[0053] In some embodiments of the present invention, the content of silica in the dosage form A of the kit described herein is 1-10% by weight. In some embodiments of the present invention, the dosage form A of the kit contains 5-10% by weight of silica.

[0054] Other ingredients in dosage form A

[0055] The dosage form A of the set of the present invention may further comprise other ingredients. For example, the dosage form A of the set of the present application may comprise oil, thickener, preservative, pH adjuster, etc.

[0056] In some specific embodiments, the oil contained in the formulation A of the set is selected from the group consisting of isononyl isononanoate, polydimethylsiloxane, or a combination thereof. In some preferred embodiments, the amount of oil in the formulation A is 10-20% by weight.

[0057] In some specific embodiments, the formulation A of the kit comprises an acrylic acid ester / C10-30 alkyl acrylate crosspolymer. In some preferred embodiments, the amount of acrylic acid ester / C10-30 alkyl acrylate crosspolymer in formulation A is 0.1-5% by weight. In some preferred embodiments, the amount of acrylic acid ester / C10-30 alkyl acrylate crosspolymer in formulation A is 0.5-1.5% by weight.

[0058] In some specific embodiments, the dosage form A of the kit contains phenoxyethanol. In some preferred embodiments, the amount of phenoxyethanol in the dosage form A is 0.1-1% by weight.

[0059] In some specific embodiments, the dosage form A of the kit comprises tromethamine. In some preferred embodiments, the amount of tromethamine in the dosage form A is 0.1-1% by weight.

[0060] Preparation method of dosage form A

[0061] The present invention also provides a method for preparing dosage form A.

[0062] The formulation A of the present invention can be prepared according to the following raw materials in weight percentage: 10-20% oil, 0.001-30% mosquito repellent, 3-25% hydrogenated polydimethylsiloxane, 5-35% vinyl polydimethylsiloxane, 1-10% silica, 2-5% emulsifier, 0.5-1.5% thickener, 0.1-1% preservative and 40-60% deionized water.

[0063] Specifically, the preparation method of dosage form A of the present invention comprises the following steps:

[0064] (a) mixing a mosquito repellent, vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, silica, oil and emulsifier to form an oil phase;

[0065] (b) taking a portion of deionized water, adding a thickener, dissolving it until fully swollen, and adding other ingredients such as a preservative to form the aqueous phase;

[0066] (c) Slowly add the aqueous phase to the oil phase to obtain formulation A.

[0067] In a specific embodiment, the preparation process of dosage form A includes the following steps: at a temperature range of 25-60°C, the mosquito repellent, vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, silica, oil and emulsifier are mixed uniformly to form the oil phase. A portion of deionized water is taken, a thickener is added, and the mixture is dissolved and fully swelled to form the aqueous phase. The remaining deionized water and preservative are mixed uniformly and added to the aqueous phase. At a temperature range of 25-60°C, the aqueous phase is slowly added to the oil phase and stirred and homogenized for 5 to 15 minutes; stirring is continued and the mixture is slowly cooled to room temperature to form a milky white cream, which is then sealed and stored away from light.

[0068] II. Dosage Form B

[0069] Formulation B in the long-lasting mosquito and insect repellent kit described in the present application is a product applied in the second step, comprising a colloidal platinum composition and light scattering particles.

[0070] Colloidal platinum composition

[0071] This application first discovered that the selection of solvents and additives is crucial during the preparation of colloidal platinum compositions. The present invention innovatively discovered that by using specific solvents (e.g., propylene glycol) and additives (e.g., fatty acids and organosilanes), the resulting colloidal platinum compositions have particle sizes within the range of 0.5-5 nm and maintain long-term stability.

[0072] In some embodiments of the present invention, the content of the colloidal platinum composition in the dosage form B of the kit described herein is 0.01-10% by weight. In some embodiments of the present invention, the dosage form B of the kit comprises 0.01-5% by weight of the colloidal platinum composition. In some embodiments of the present invention, the dosage form B of the kit comprises 1-5% by weight of the colloidal platinum composition.

[0073] Metal platinum salts of colloidal platinum compositions

[0074] The invention provides a colloidal platinum composition, which contains colloidal platinum, a raw material specially used for top-grade cosmetics, as an active ingredient.

[0075] In an embodiment of the present invention, the metal platinum salt is selected from: chloroplatinic acid (cas: 16941-12-1, chemical formula: H2PtCl6·6H2O), potassium hexachloroplatinate (cas: 16921-30-5, chemical formula: K2PtCl6), sodium chloroplatinate (cas: 19583-77-8, chemical formula: Na2PtCl6·6H2O), acetylacetonate (cas: 15170-57-7, chemical formula: C 10 H 14 In a preferred embodiment, the metal platinum salt is chloroplatinic acid.

[0076] In some embodiments of the present invention, the colloidal platinum composition described herein comprises a metal platinum salt in an amount of 0.1-10% by weight. In some embodiments of the present invention, the colloidal platinum composition comprises a metal platinum salt in an amount of 0.1-8% by weight. In some embodiments of the present invention, the composition comprises a metal platinum salt in an amount of 0.1-5% by weight. In some embodiments of the present invention, the composition comprises a metal platinum salt in an amount of 0.1-4% by weight.

[0077] Solvent for colloidal platinum composition

[0078] Colloidal platinum is a liquid containing negatively charged platinum nanoparticles suspended in it. Ethylene glycol is commonly used as a solvent for preparing colloidal platinum compositions. For example, the use of ethylene glycol is reported in the literature (Nano Today, 2009, 4, 143-164). However, ethylene glycol is toxic and can damage internal organs such as the kidneys, liver, stomach, and intestines. Furthermore, ethylene glycol is listed as a restricted organic solvent in the Appendix to Part II of the 2010 edition of the Chinese Pharmacopoeia.

[0079] Propylene glycol, whose INCI name is PROPYLENE GLYCOL. The present applicant unexpectedly discovered that using propylene glycol as a solvent for preparing colloidal platinum compositions not only retains the advantages of propylene glycol, such as being non-toxic, non-corrosive, biodegradable, and safer, but also maintains the stability of the prepared colloidal platinum compositions. Therefore, the present applicant discovered for the first time that propylene glycol is the optimal solvent for preparing colloidal platinum compositions.

[0080] In some embodiments of the present invention, the amount of solvent in the colloidal platinum composition described herein is equal to or greater than 50% by weight. In some embodiments of the present invention, the colloidal platinum composition comprises 40-95% by weight of solvent. In some embodiments of the present invention, the composition comprises 50-90% by weight of solvent. In some embodiments of the present invention, the composition comprises 60-90% by weight of solvent. In some embodiments of the present invention, the composition comprises 70-90% by weight of solvent.

[0081] Additives to colloidal platinum compositions

[0082] The present invention unexpectedly discovered that fatty acids and organosilanes play a key role in the preparation of colloidal platinum compositions.

[0083] The addition of fatty acids plays a key role in controlling the particle size of colloidal platinum.

[0084] Fatty acids are a class of compounds composed of three elements: carbon, hydrogen, and oxygen. They are the main components of neutral fats, phospholipids, and glycolipids. Fatty acid metabolism Fatty acids can be divided into the following categories according to the length of their carbon chains: short-chain fatty acids, which have less than 6 carbon atoms on their carbon chains, also known as volatile fatty acids; medium-chain fatty acids, which refer to fatty acids with 6-12 carbon atoms on their carbon chains, the main components of which are caprylic acid (C8) and capric acid (C10); and long-chain fatty acids, which have more than 12 carbon atoms on their carbon chains. In a preferred embodiment of the present invention, the additives used are medium-chain or long-chain fatty acids. In a preferred embodiment, fatty acids with 8-30 carbon atoms are used. In a more preferred embodiment, fatty acids with 10-26 carbon atoms are used. In a more preferred embodiment, fatty acids with 12-22 carbon atoms are used. In a specific embodiment, fatty acids with 12, 14, 16, 18, 20, or 22 carbon atoms are used.

[0085] Fatty acids can be divided into three categories based on whether their carbon-hydrogen chains are saturated or unsaturated: saturated fatty acids, which have no unsaturated bonds between carbon and hydrogen; monounsaturated fatty acids, which have one unsaturated bond between carbon and hydrogen; and polyunsaturated fatty acids, which have two or more unsaturated bonds between carbon and hydrogen. Saturated, monounsaturated, or polyunsaturated fatty acids can be used in the colloidal platinum compositions of the present invention.

[0086] In a preferred embodiment, the fatty acid is selected from the group consisting of palmitic acid, oleic acid, stearic acid, lauric acid, behenic acid, or a combination thereof. In a most preferred embodiment, the fatty acid is oleic acid.

[0087] In some embodiments of the present invention, the amount of fatty acid in the colloidal platinum composition described herein is 1-20% by weight. In some embodiments of the present invention, the colloidal platinum composition comprises 1-15% by weight of fatty acid. In some embodiments of the present invention, the composition comprises 2-15% by weight of fatty acid. In some embodiments of the present invention, the composition comprises 3-10% by weight of fatty acid. In some embodiments of the present invention, the composition comprises 5-10% by weight of fatty acid.

[0088] The addition of organosilane helps to maintain the long-term stability of colloidal platinum activity.

[0089] In some embodiments of the present invention, organosilanes having 10-60 carbon atoms are used. In preferred embodiments, organosilanes having 10-30 carbon atoms are used. In more preferred embodiments, organosilanes having 10-26 carbon atoms are used. In still more preferred embodiments, organosilanes having 10-20 carbon atoms are used. In specific embodiments, organosilanes having 11, 14, 17, or 20 carbon atoms are used.

[0090] In a preferred embodiment, the organosilane is selected from: trimethoxyoctylsilane, triethoxyoctylsilane or a combination thereof. In a more preferred embodiment, the organosilane is trimethoxyoctylsilane.

[0091] In some embodiments of the present invention, the amount of organosilane in the colloidal platinum composition described herein is 0.01-5% by weight. In some embodiments of the present invention, the colloidal platinum composition comprises 0.01-1% by weight of the organosilane. In some embodiments of the present invention, the colloidal platinum composition comprises 0.1-2% by weight of the organosilane. In some embodiments of the present invention, the composition comprises 0.1-1% by weight of the organosilane. In some embodiments of the present invention, the composition comprises 0.1-0.5% by weight of the organosilane.

[0092] Other ingredients in colloidal platinum compositions

[0093] The colloidal platinum composition of the present invention may further comprise other ingredients.

[0094] For example, in one embodiment of the present invention, the composition further comprises polyvinylpyrrolidone. Polyvinylpyrrolidone, abbreviated as PVP, is a non-ionic polymer compound. PVP is divided into four grades according to its average molecular weight, which is usually expressed as a K value. Different K values represent the corresponding range of PVP average molecular weight. The K value is actually a characteristic value related to the relative viscosity of the PVP aqueous solution. Viscosity is a physical quantity related to the molecular weight of the polymer. Therefore, the K value can be used to characterize the average molecular weight of PVP. Generally, the larger the K value, the greater the viscosity and the stronger the adhesion.

[0095] In a specific embodiment, the K value of the polyvinyl pyrrolidone contained in the composition is required to be in the range of 28-34.

[0096] In some embodiments of the present invention, the amount of polyvinyl pyrrolidone in the colloidal platinum composition described herein is 1-30% by weight. In some embodiments of the present invention, the colloidal platinum composition comprises 2-30% by weight of polyvinyl pyrrolidone. In some embodiments of the present invention, the composition comprises 2-20% by weight of polyvinyl pyrrolidone. In some embodiments of the present invention, the composition comprises 2-15% by weight of polyvinyl pyrrolidone. In some embodiments of the present invention, the composition comprises 1-10% by weight of polyvinyl pyrrolidone.

[0097] Preparation method of colloidal platinum composition

[0098] The present invention also provides a method for preparing the colloidal platinum composition.

[0099] The colloidal platinum composition of the present invention can be prepared according to the following raw materials in weight percentage: 0.1%-4% of metal platinum salt, 2%-30% of polyvinyl pyrrolidone, 60%-90% of propylene glycol, 5%-15% of fatty acid, and 0.01%-1% of organosilane.

[0100] Specifically, the method for preparing the colloidal platinum composition of the present invention comprises the following steps:

[0101] (a) mixing a metal platinum salt, polyvinyl pyrrolidone, and propylene glycol to obtain a first mixture;

[0102] (b) adding a fatty acid to the first mixture to obtain a second mixture;

[0103] (c) adding organosilane to the second mixture to finally obtain the colloidal platinum composition of the present invention.

[0104] In one embodiment, the method for preparing a colloidal platinum composition of the present invention comprises the following steps: uniformly mixing a metal platinum salt, polyvinyl pyrrolidone, and propylene glycol at room temperature in the aforementioned amounts; rapidly stirring, heating to 110-200°C, and maintaining the temperature for 2-8 hours; adding a fatty acid, raising the temperature to 120-250°C, and continuing stirring for 30-90 minutes; then cooling the mixture to 60-80°C, adding an organosilane, and maintaining the temperature with stirring for 30-90 minutes; finally, cooling the mixture to room temperature; discharging the mixture, and the colloidal platinum is completed. Store in a cool, dark place.

[0105] The colloidal platinum composition prepared by the present invention has an average particle size of 0.5-5 nm. In a preferred embodiment, the colloidal platinum composition of the present invention has an average particle size of 1-5 nm. In a preferred embodiment, the colloidal platinum composition of the present invention has an average particle size of 1-3 nm.

[0106] In the colloidal platinum composition prepared by the present invention, more than 75% of the particles have a particle size within the range of 1.75 ± 0.5 nm. In a preferred embodiment, more than 80% of the particles in the composition have a particle size within the range of 1.75 ± 0.5 nm. In a more preferred embodiment, more than 90% of the particles in the composition have a particle size within the range of 1.75 ± 0.5 nm.

[0107] Light scattering particles

[0108] The formulation B in the long-lasting mosquito repellent kit described herein comprises light-scattering particles. In some embodiments of the present invention, the light-scattering particles comprise: nylon-12, isopropyl titanium triisostearate, silicone resin, or a combination thereof.

[0109] In some embodiments of the present invention, the light scattering particles in the dosage form B of the set described herein are present in an amount of 1-10% by weight. In some embodiments of the present invention, the dosage form A of the set comprises 2-8% by weight of light scattering particles. In some embodiments of the present invention, the dosage form A of the set comprises 2-5% by weight of light scattering particles.

[0110] Other ingredients in dosage form B

[0111] The formulation B of the set of the present invention may further comprise other ingredients. For example, the formulation A of the set of the present application may comprise silicone oil, silicone elastomer, emulsifier, polyol, preservative, and the like.

[0112] In some embodiments of the present invention, the formulation B of the kit comprises cyclopentasiloxane. In some specific embodiments, the formulation B comprises 10-20% by weight of cyclopentasiloxane.

[0113] In some embodiments of the present invention, the formulation B of the kit comprises dimethicone crosspolymer. In some specific embodiments, the formulation B comprises 1-15% by weight of dimethicone crosspolymer.

[0114] In some embodiments of the present invention, the polyol contained in the formulation B of the kit is selected from glycerol, butylene glycol, hexylene glycol or a combination thereof. In some specific embodiments, the formulation B contains 20-40% by weight of the polyol.

[0115] In some embodiments of the present invention, the emulsifier contained in the formulation B of the kit is selected from the group consisting of: cetyl PEG / PPG-10 / 1 dimethicone, dimethicone PEG-10 / 15 crosspolymer, or a combination thereof. In some specific embodiments, formulation B contains 2-5% by weight of the emulsifier.

[0116] Preparation method of dosage form B

[0117] The present invention also provides a preparation method of dosage form B.

[0118] The formulation B of the present invention can be prepared according to the following raw materials in weight percentage: silicone oil 10-20%, silicone elastomer 1-15%, emulsifier 2-5%, light scattering particles 2-8%, colloidal platinum composition 0.01-2%, polyol 20-40%, preservative 0.1-1%, and deionized water 25-45%.

[0119] Specifically, the preparation method of dosage form B of the present invention comprises the following steps:

[0120] (a) mixing silicone oil, silicone elastomer, emulsifier, and light scattering particles to form an oil phase;

[0121] (b) taking a portion of deionized water, adding a polyol and a preservative, and dissolving them fully to form the aqueous phase;

[0122] (c) preparing a colloidal platinum composition as an additive phase;

[0123] (d) The aqueous phase was slowly added to the oil phase, and then the additive phase was added to obtain formulation B.

[0124] In one specific embodiment, the preparation process of Formulation B comprises the following steps: uniformly mixing silicone oil, silicone elastomer, emulsifier, and light-scattering particles at a temperature range of 25-60°C to form the oil phase. A polyol and preservative are added to a portion of deionized water and dissolved thoroughly to form the aqueous phase. Colloidal platinum is added separately to form the additive phase. The aqueous phase is slowly added to the oil phase at a temperature range of 25-60°C, stirring and homogenizing for 5-15 minutes; the additive phase is then added, stirring and homogenizing continued for 5-15 minutes, and an opaque gel is formed, which is then sealed and stored away from light.

[0125] III. Application of the Set

[0126] The present invention also relates to the use of the long-lasting mosquito repellent kit in the personal care field. Specifically, the application method includes first applying Formulation A to the desired area of skin. After complete absorption, apply Formulation B to the desired area, for example, and wait for 3 to 10 minutes. The kit of the present invention can achieve a long-lasting mosquito repellent effect, for example, lasting 4 hours or more, 8 hours or more, 12 hours or more, or 15 hours or more.

[0127] Long-lasting insect repellent, non-irritating to the skin, and perfect skin protection. The technology of this invention forms a transparent, invisible film on the skin's surface, preventing the repellent from penetrating the skin while also allowing it to remain on the skin for extended periods of time, ensuring its effectiveness. Even in complex outdoor environments, the repellent remains effectively on the skin's surface, resisting washout or loss that could reduce its effectiveness.

[0128] The present invention will be further described below with reference to specific examples. It should be noted that the examples are intended only to further illustrate the present invention and are not to be construed as limiting the scope of the present invention. Those skilled in the art may make non-essential improvements and adjustments based on the above-described disclosure of the present invention. The test methods in the following examples, for which specific conditions are not specified, are generally based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise indicated, all percentages and parts are by weight.

[0129] Example 1: Preparation of colloidal platinum composition

[0130] At room temperature, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 85.5% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 8% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 0.5% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0131] Comparative Example 1: Preparation of colloidal platinum composition

[0132] At room temperature, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 86% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 8% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Finally, cool to room temperature. Discard the mixture, and colloidal platinum is ready. Store in a cool, dark place.

[0133] Comparative Example 2: Preparation of Colloidal Platinum Composition

[0134] At room temperature, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 93.5% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Then, cool to 60°C, add 0.5% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0135] Comparative Example 3: Preparation of Colloidal Platinum Composition

[0136] At room temperature, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 94% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Finally, cool to room temperature. Discard the solution, and colloidal platinum is ready. Store in a cool, dark place.

[0137] Test Example 1: Stability Study of Colloidal Platinum Composition

[0138] The stability evaluation method is as follows: The colloidal platinum compositions prepared in Example 1 and Comparative Examples 1-3 were placed in a stable, high-temperature (40°C) thermostat for 30 days. The samples were observed for signs of solid precipitation, surface blackening, and delamination. If the sample remained normal and unchanged before and after a certain time within the 30-day period, it was considered "OK." The presence of particles indicated "precipitation," localized blackening indicated "blackening," and the presence of two layers of liquid indicated "delamination." The results are shown in the table below.

[0139] Table 1: Stability study of different additives

[0140]

[0141] As shown in Table 1, by comparing the results of Example 1 and Comparative Example 1, it is found that if no organosilane is added as a stabilizer to the colloidal platinum composition, the colloidal platinum composition will turn black after 30 days. By comparing the results of Example 1 and Comparative Example 2, it is found that if no fatty acid is added during the preparation of the colloidal platinum composition, solid precipitation and agglomeration will occur after 7 days. By comparing the results of Example 1 and Comparative Example 3, it is shown that the addition of fatty acid and organosilane during the preparation process of the colloidal platinum composition plays an important role in the stability of the colloidal platinum composition.

[0142] Example 2: Preparation of colloidal platinum composition

[0143] At room temperature, mix 0.5% potassium hexachloroplatinate, 3% polyvinylpyrrolidone, and 90.2% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 6% stearic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 0.3% triethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0144] Example 3: Preparation of colloidal platinum composition

[0145] At room temperature, mix 2.5% sodium chloroplatinate, 15% polyvinylpyrrolidone, and 67.5% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 14% lauric acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 1% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0146] Example 4: Preparation of colloidal platinum composition

[0147] At room temperature, mix 3% platinum acetylacetonate, 20% polyvinylpyrrolidone, and 66.1% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 10% behenic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 0.9% triethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0148] Example 5: Preparation of colloidal platinum composition

[0149] At room temperature, mix 0.5% chloroplatinic acid, 0.2% platinum acetylacetonate, 10% polyvinylpyrrolidone, and 76.5% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 2% palmitic acid and 10% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 0.8% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0150] Example 6: Preparation of colloidal platinum composition

[0151] At room temperature, mix 0.1% sodium chloroplatinate, 0.1% platinum acetylacetonate, 3% polyvinylpyrrolidone, and 92.7% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 1% stearic acid and 3% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 0.1% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the mixture, and colloidal platinum is ready. Store in a cool, dark place.

[0152] Example 7: Preparation of colloidal platinum composition

[0153] At room temperature, mix 2% chloroplatinic acid, 2% sodium chloroplatinate, 30% polyvinylpyrrolidone, and 50% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 15% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 1% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0154] Test Example 2: Stability Study of Colloidal Platinum Composition

[0155] The stability evaluation method is as follows: The colloidal platinum compositions prepared in Examples 2-7 were placed in a stable, high-temperature (40°C) thermostat for 30 days. The samples were observed for signs of solid precipitation, surface blackening, and delamination. If the samples remained normal and unchanged before and after a certain time within the 30-day period, they were considered "OK." The presence of particles indicated precipitation, localized blackening indicated darkening, and the presence of two layers of liquid indicated delamination. The results are shown in Table 2 below.

[0156] Table 2: Stability study of different raw materials

[0157]

[0158]

[0159] As shown in Table 2, the results of Examples 2 to 5 indicate that the metal platinum salt selected for the colloidal platinum can be selected from chloroplatinic acid, potassium hexachloroplatinate, sodium chloroplatinate, and platinum acetylacetonate, all of which can achieve good results. The results of Examples 4, 6, and 7 indicate that trimethoxyoctylsilane and triethoxyoctylsilane can both produce colloidal platinum compositions with good stability. Comparison of all the above results indicates that, in the process of preparing colloidal platinum, fatty acids selected from palmitic acid, oleic acid, stearic acid, lauric acid, and behenic acid can all achieve satisfactory results.

[0160] The colloidal platinum compositions obtained in the above experiments not only exhibit excellent stability but also maintain a high level of activity. Because colloidal platinum can promote the cross-linking reaction of siloxanes, a personal care product containing siloxane was used as the first dosage form (Formulation A), followed by a personal care product containing the colloidal platinum composition as the second dosage form (Formulation B).

[0161] This study has designed a dual-formulation product: Formulation A, which contains silicone, and Formulation B, which contains a colloidal platinum compound. Formulation A is pre-applied to a designated skin area, followed by an equal amount of Formulation B. The colloidal platinum compound promotes cross-linking of silicone on the skin surface, providing water-resistant, sweat-resistant, and long-lasting insect repellency.

[0162] The following are examples of specific applications of the colloidal platinum composition of the present invention in external skin preparations, as well as the formulations and preparation methods of these preparations. In the following tables, "-" indicates no additive.

[0163] Table 3: Formulation A (Product Examples 4 / 5 / 6 / 7, Application Example 1)

[0164]

[0165]

[0166] Table 4: Formulation composition information of dosage form B (product examples 5-7 and application example 1)

[0167]

[0168] Product Example 4:

[0169] Preparation of dosage form A

[0170] According to the above formula and dosage, 10% of Imonin and 60% of alcohol were fully mixed, and 30% of water phase was added until uniform. The mixture was sealed and stored away from light.

[0171] Product Example 5:

[0172] Preparation of dosage form A

[0173] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 20% vinyl dimethicone (viscosity: 10,000 cSt), 10.00% hydrogenated dimethicone (viscosity: 45 cSt), 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% imipramine, and 4% dimethicone PEG-10 / 15 crosspolymer to form the oil phase. Add acrylates / C10-30 alkyl acrylate crosspolymer to 30% deionized water and dissolve until fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0174] Preparation of dosage form B

[0175] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 52.9% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 1% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0176] Product Example 6:

[0177] Preparation of dosage form A

[0178] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 20% vinyl dimethicone (viscosity: 180,000 cSt), 10% hydrogenated dimethicone (viscosity: 45 cSt), 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% imipramine, and 4% dimethicone PEG-10 / 15 crosspolymer to form the oil phase. Add acrylates / C10-30 alkyl acrylate crosspolymer to 30% deionized water and dissolve until fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0179] Preparation of dosage form B

[0180] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 52.9% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 1% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0181] Product Example 7:

[0182] Preparation of dosage form A

[0183] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 20% vinyl dimethicone (viscosity: 60,000 cSt), 10% hydrogenated dimethicone (viscosity: 45 cSt), 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% imipramine, and 4% dimethicone PEG-10 / 15 crosspolymer to form the oil phase. Add acrylates / C10-30 alkyl acrylate crosspolymer to 30% deionized water and dissolve until fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0184] Preparation of dosage form B

[0185] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 52.9% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 1% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0186] Application Example 1:

[0187] Preparation of dosage form A

[0188] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 20% vinyl dimethicone (viscosity: 60,000 cSt), 10% hydrogenated dimethicone (viscosity: 45 cSt), 8% silica, 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% immonin, and 4% dimethicone PEG-10 / 15 crosspolymer to form the oil phase. Add 0.5% acrylates / C10-30 alkyl acrylate crosspolymer to 25% deionized water and dissolve until fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0189] Preparation of dosage form B

[0190] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 52.9% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 1% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0191] Test Example 3:

[0192] Test method: The tests were carried out simultaneously, and the test methods all adopted GB / T1391.9-2009.

[0193] 2.1 Attack power test

[0194] Place 300 test insects in a mosquito cage. The tester exposes 40mm x 40mm of skin on the back of their hand, with the rest of their hand tightly covered. Place their hand in the cage for 2 minutes and observe closely. If a mosquito lands, shake their hand to dislodge it before its mouthparts penetrate their skin. This counts as one landing insect. If more than 30 test insects land on the tester and the test insects, their aggression is considered acceptable, and this person and the mosquito cage can be used in the repellency test.

[0195] 2.2 Repellency test

[0196] Eight or more testers with acceptable aggression resistance were selected (half male and half female, and they should refrain from alcohol, tea, or coffee, or products containing fragrances, before and during the test). A 50 mm x 50 mm skin area was drawn on the back of each hand. On one hand, a 1.5 mg / cm² (paste repellent) or 1.5 μL / cm² (liquid repellent) repellent was evenly applied to the test hand, leaving the remaining 40 mm x 40 mm of skin exposed. The other hand served as a blank control. Two hours after the repellent application, the hand was placed in a mosquito cage with acceptable aggression resistance for two minutes, and observation was made for mosquitoes landing and feeding. Testing was then repeated every hour thereafter. If even one mosquito fed, the repellent was deemed ineffective. The effective protection time (hours) of the repellent was recorded. A control hand was used for each test. Test insects with acceptable aggression resistance continued in the test; test insects with unacceptable aggression resistance were replaced with qualified test insects.

[0197] 2.3 Waterproof test

[0198] Eight or more testers with acceptable aggression resistance (half male and half female, and refraining from alcohol, tea, or coffee, or products containing fragrances, before and during the test) were selected. A 50 mm x 50 mm skin area was drawn on the back of each hand. On one hand, a 1.5 mg / cm² (paste repellent) or 1.5 μL / cm² (liquid repellent) dose of the repellent to be tested was evenly applied to the skin, exposing a 40 mm x 40 mm area and closely covering the remaining area. The other hand served as a blank control. After application, the tester placed the test area in water with moderate activity or moderate rotation for 20 minutes. The tester then emerged from the water and allowed the skin to dry (do not rub the test area with a towel). After 2 hours, the tester placed their hand in a mosquito cage with acceptable aggression resistance for 2 minutes, observing for mosquitoes landing and feeding. Testing was repeated every hour thereafter; if even one mosquito fed, the repellent was deemed ineffective. The effective protection duration (hours) of the repellent was recorded. Each time, a control test is performed first. Test insects with qualified attack power can continue the test. Test insects with unqualified attack power need to be replaced with qualified test insects for testing.

[0199] Table 5. Experimental results of repellency test

[0200]

[0201] As can be seen from Table 5, for the test before bathing, the samples of the present invention (No. 2 to 5) all have excellent mosquito repellent performance, which is significantly better than the formula of the aqueous solution of imonenol in Product Example 4. By comparing the experimental results between Product Examples 5 to 7, the viscosity of vinyl polydimethylsiloxane has a certain influence on the final mosquito repellent time value. Selecting a relatively low viscosity (10,000 cSt) or a relatively high viscosity (180,000 cSt) is relatively unfavorable for the film formation of the mosquito repellent film. Selecting a moderate viscosity (60,000 cSt) can maintain good spreadability and moldability, and the final mosquito repellent effect is better. According to the results of Product Example 7 and Application Example 1, the addition of silica has no significant effect on the mosquito repellent time value before bathing.

[0202] In tests after bathing, it was found that Product Examples 4 to 7 and Application Example 1 all showed varying degrees of decrease in the mosquito repellent time. The viscosity of the vinyl polydimethylsiloxane has a certain impact on the final mosquito repellent time. Selecting a relatively low viscosity (10,000 cSt) or a relatively high viscosity (180,000 cSt) is relatively unfavorable for the film formation of the mosquito-repellent film. Selecting a moderate viscosity (60,000 cSt) can maintain good spreadability and moldability, resulting in a relatively higher final mosquito repellent time. Furthermore, a comparison of Product Example 7 and Application Example 1 revealed that the addition of silica can help increase the mosquito repellent time after bathing, maintaining the mosquito repellent time at the level before bathing. This indicates that the mosquito repellent effect of the present invention is not significantly affected when exposed to water. It has the advantage of strong water resistance, capable of withstanding the erosion and damage of external rainwater, seawater, dust, and some mechanical stresses, thereby achieving a waterproof and sweat-resistant mosquito repellent effect.

[0203] Application Example 2:

[0204] Preparation of dosage form A

[0205] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 35% vinyl dimethicone (viscosity: 65,000 cSt), 25% hydrogenated dimethicone (viscosity: 45 cSt), 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% immonin, 4% dimethicone PEG-10 / 15 crosspolymer, and 10% silica silylate to form the oil phase. Add 0.2% acrylates / C10-30 alkyl acrylate crosspolymer to 3% deionized water and dissolve until fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0206] Preparation of dosage form B

[0207] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 48.9% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 5% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0208] Application Example 3:

[0209] Preparation of dosage form A

[0210] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 5% vinyl dimethicone (viscosity: 80,000 cSt), 3% hydrogenated dimethicone (viscosity: 100 cSt), 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% immonin, 2% dimethicone PEG-10 / 15 crosspolymer, and 1% silica dimethyl silylate to form the oil phase. Add 0.5% acrylates / C10-30 alkyl acrylate crosspolymer to 40% deionized water and dissolve until fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0211] Preparation of dosage form B

[0212] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 53.8% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 0.1% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0213] Application Example 4: Preparation of Dosage Form A

[0214] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 20% vinyl dimethicone (viscosity: 80,000 cSt), 10% hydrogenated dimethicone (viscosity: 15 cSt), 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% imipramine, 4% dimethicone PEG-10 / 15 crosspolymer, and 5% dimethicone silica silylate to form the oil phase. Add 0.5% acrylates / C10-30 alkyl acrylate crosspolymer to 30% deionized water and dissolve until fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0215] Preparation of dosage form B

[0216] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, and 3% silicone resin particles to form the oil phase. Fully dissolve 53.4% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately add 2% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0217] Application Example 5: Preparation of Dosage Form A

[0218] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 12% vinyl dimethicone (viscosity: 65,000 cSt), 8% hydrogenated dimethicone (viscosity: 45 cSt), 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% immonin, 4% dimethicone PEG-10 / 15 crosspolymer, and 5% dimethicone silica silylate to form the oil phase. Add 0.5% acrylates / C10-30 alkyl acrylate crosspolymer to 30% deionized water and dissolve until fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0219] Preparation of dosage form B

[0220] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 10% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Fully dissolve 47.4% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately add 1% of the colloidal platinum composition of Example 5 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0221] Application Example 6: Preparation of Dosage Form A

[0222] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 20% vinyl dimethicone (viscosity: 60,000 cSt), 10% hydrogenated dimethicone, 8% silica, 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% DEET, and 4% dimethicone PEG-10 / 15 crosspolymer to form the oil phase. Add 0.5% acrylates / C10-30 alkyl acrylate crosspolymer to 25% deionized water and dissolve until fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0223] Preparation of dosage form B

[0224] At a temperature between 45°C and 60°C, mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 1% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 56.4% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Add 1% of the colloidal platinum composition of Example 6 separately to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Store sealed and protected from light.

[0225] Application Example 7:

[0226] Preparation of dosage form A

[0227] According to the above formulation, 20% vinyl dimethicone (viscosity: 60,000 cSt), 10% hydrogenated dimethicone (viscosity: 45 cSt), 8% silica, 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% hydroxyphenoxylate, and 4% dimethicone PEG-10 / 15 crosspolymer were thoroughly mixed at a temperature range of 25°C to 60°C to form the oil phase. 0.5% acrylates / C10-30 alkyl acrylate crosspolymer was added to 25% deionized water and dissolved until fully swollen to form the aqueous phase. The remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol were then mixed and the aqueous phase was added. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0228] Preparation of dosage form B

[0229] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 48.9% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 5% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0230] Application Example 8: Preparation of Dosage Form A

[0231] According to the above formulation, 20% vinyl dimethicone (viscosity: 60,000 cSt), 10% hydrogenated dimethicone (viscosity: 45 cSt), 8% silica, 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% PMD, and 4% dimethicone PEG-10 / 15 crosspolymer are thoroughly mixed in a temperature range of 25°C to 60°C to form the oil phase. 25% deionized water is then added, and 0.5% acrylic acid (ester) / C10-30 alkyl acrylate crosspolymer is dissolved and fully swelled to form the aqueous phase. The remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol are then mixed and the aqueous phase is further added. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0232] Preparation of dosage form B

[0233] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 53.8% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 0.1% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0234] Application Example 9:

[0235] Preparation of dosage form A

[0236] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 20% vinyl dimethicone (viscosity: 60,000 cSt), 10% hydrogenated dimethicone (viscosity: 45 cSt), 8% silica, 5.00% dimethicone, 5.00% isononyl isononanoate, 10.00% lemon eucalyptus oil, and 4% dimethicone PEG-10 / 15 crosspolymer to form the oil phase. Add 0.5% acrylates / C10-30 alkyl acrylate crosspolymer to 25% deionized water and dissolve until fully swollen to form the aqueous phase. Then, thoroughly mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0237] Preparation of dosage form B

[0238] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, and 3% silicone resin particles to form the oil phase. Fully dissolve 53.4% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately add 2% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0239] Application Example 10:

[0240] Preparation of dosage form A

[0241] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 15% vinyl dimethicone (viscosity: 60,000 cSt), 7% hydrogenated dimethicone (viscosity: 45 cSt), 3.00% dimethicone, 3.00% isononyl isononanoate, 30.00% imipramine, and 4% dimethicone PEG-10 / 15 crosspolymer to form the oil phase. Add 0.5% acrylates / C10-30 alkyl acrylate crosspolymer to 25% deionized water and dissolve until fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0242] Preparation of dosage form B

[0243] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 10% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Fully dissolve 47.4% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately add 1% of the colloidal platinum composition of Example 5 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0244] Application Example 11:

[0245] Preparation of dosage form A

[0246] According to the above formulation, at a temperature range of 25°C to 60°C, thoroughly mix 20% vinyl dimethicone (viscosity: 60,000 cSt), 10% hydrogenated dimethicone (viscosity: 45 cSt), 8% silica, 5.00% dimethicone, 5.00% isononyl isononanoate, 0.0001% imonine, and 4% dimethicone PEG-10 / 15 crosspolymer to form the oil phase. Add 0.5% acrylates / C10-30 alkyl acrylate crosspolymer to 25% deionized water and dissolve until fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. In the temperature range of 25℃~60℃, slowly add the water phase into the oil phase, stir and homogenize for 5~15 minutes; continue stirring and slowly cool to room temperature to form a milky white cream, and store in a sealed place away from light.

[0247] Preparation of dosage form B

[0248] At a temperature between 45°C and 60°C, mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 1% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 56.4% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Add 1% of the colloidal platinum composition of Example 6 separately to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Store sealed and protected from light.

[0249] Test Example 4:

[0250] Test method: The tests were carried out simultaneously, and the test methods all adopted GB / T1391.9-2009.

[0251] The details are exactly the same as those described in Test Example 3. The samples of Application Examples 2 to 11 were tested, and the results are shown in Table 6:

[0252] Table 6. Experimental results of repellency test

[0253]

[0254] As can be seen from Table 6, in the test before bathing, the samples of the present invention (Application Examples 2 to 11) all have excellent mosquito repellent performance, and can repel mosquitoes for at least more than 9 hours.

[0255] In the test after bathing, it was found that the mosquito repellent time value decreased slightly, but still maintained at more than 8 hours (Application Examples 2 to 11). This shows that the mosquito repellent effect of the present invention is not significantly affected when exposed to water. It has the advantage of strong water resistance and can resist the erosion and damage of rain, seawater, dust and some mechanical stresses, thereby achieving waterproof and sweat-resistant mosquito repellent effects.

Claims

1. A long-lasting mosquito and insect repellent kit comprising: (i) Dosage Form A, comprising: 10-20% by weight of fat, 0.01-30% by weight of an insect repellent, 3-25% by weight of hydrogenated polydimethylsiloxane having a viscosity of 10 to 130 cSt at 25°C, 5-35% by weight of vinyl polydimethylsiloxane having a viscosity of 55,000 to 95,000 cSt at 25°C, 1-10% by weight of an emulsifier, and A personal care acceptable carrier; and (ii) Dosage Form B, comprising: 1-10% by weight of a colloidal platinum composition, 1-10% by weight of light scattering particles, An acceptable carrier in the field of personal care; Wherein, the colloidal platinum composition comprises: 0.1-10% by weight of a metal platinum salt or chloroplatinic acid, 1-20% by weight of fatty acids having 8-30 carbon atoms, 0.01-5% by weight of an organosilane having 10-60 carbon atoms, A solvent acceptable in the field of personal care, said solvent being propylene glycol, Wherein, the metal platinum salt is selected from: potassium hexachloroplatinate, sodium chloroplatinate, platinum acetylacetonate or a combination thereof.

2. The set according to claim 1, wherein: The dosage form A further comprises 1-10% by weight of silica.

3. The set according to claim 1, wherein: The emulsifier in Formulation A is dimethicone PEG-10 / 15 crosspolymer.

4. The set according to claim 2, wherein: The silica in the dosage form A is selected from the group consisting of silica silylate, silica dimethyl silylate, silica polydimethylsiloxane silylate, hydrated silica or a combination thereof.

5. The set according to claim 1, wherein: The colloidal platinum composition in Formulation B further comprises polyvinyl pyrrolidone having a K value of 28-34.

6. The kit according to claim 1, wherein: The fatty acid in the colloidal platinum composition in the dosage form B is selected from palmitic acid, oleic acid, stearic acid, lauric acid, behenic acid or a combination thereof.

7. The kit according to claim 1, wherein: The organosilane in the colloidal platinum composition in the formulation B is selected from: trimethoxyoctylsilane, triethoxyoctylsilane or a combination thereof.

8. The set according to claim 1, wherein: The light scattering particles in the formulation B are nylon-12 and isopropyl titanium triisostearate.

9. The set according to claim 1, wherein: The formulation B further comprises the following ingredients: silicone oil, silicone elastomer, emulsifier, polyol or a combination thereof.

10. The set according to any one of claims 1 to 9, which is in the form of a double-dose package or two separate packages.

11. Use of the kit according to any one of claims 1 to 9 in the preparation of personal care products for achieving a long-lasting mosquito and insect repellent effect.

Images